# US 2023/0399312 A1 · Substituted pyrimidines and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0399312 A1
- Document ID: US20230399312A1
- Status: Published application
- Kind: A1
- Application number: 18/140,423
- Filed: 2023-04-27
- Published: 2023-12-14
- Earliest claimed: 2020-03-31
- Assignees: Theravance Biopharma R&D IP, LLC
- Applicants: Theravance Biopharma R&D IP, LLC
- Inventors: Mandy Loo; Svitlana Kulyk; Christopher Bailey; Jennifer Kozak; Matthew B. Soellner; Adam D. Hughes
- Web page: https://patentgrep.com/patent/US20230399312A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/48: Two nitrogen atoms
- C07D 409/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/10: Spiro-condensed systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
A is selected from phenyl, 5- to 6-membered heteroaryl, indanyl, indazolyl, benzotriazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxanyl, and tetrahydrobenzazepinyl;
B is selected from phenyl and 5- to 6-membered heteroaryl;
RA is independently selected at each occurrence from:
halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —S(═O)2NR2R3, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2, —C(O)NR2R3;
C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, —C(O)OR1, C3-8 carbocycle, and 3- to 10-membered heterocycle; and
C3-8 carbocycle and 3- to 10-membered heterocycle,
wherein each C3-8 carbocycle and 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —CH2N(R1)2, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, R1, and C1-6 alkyl;
RB is independently selected at each occurrence from halogen, —CN, —NH2, —NHCH3, —NHCH2CH3, —C(O)CH3, —OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CH2F, —CHF2, —CF3, C3-4 carbocycle, and 3- to 4-membered heterocycle;
m is 0, 1 or 2;
n is 0, 1, 2, or 3;
R1 is independently selected at each occurrence from hydrogen; and C1-6 alkyl, 1- to 6-membered heteroalkyl, C0-3 alkyl-(C3-8 carbocycle), and C0-3 alkyl-(3- to 10-membered heterocycle), each of which is optionally substituted by one or more substituents selected from —NH2, —NHCH3, —N(CH3)2, —CH2CH2N(CH3)2, —C(O)CH3, —C(O)OH, —C(O)NH2, ═O, —OH, —CH2OH, —CH2CH2OH, —OCH3, —OCH2CH3, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, C3-8 carbocycle, and 3- to 6-membered heterocycle; and
R2 and R3 are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R1.

### Claim at position 2

-3. (canceled)

### Claim 4 (depends on 1)

The compound or salt of claim 1, wherein A is selected from phenyl and 5- to 6-membered heteroaryl.

### Claim 5 (depends on 1)

The compound or salt of claim 1, wherein A is selected from phenyl, indanyl, thiazolyl, thiophenyl, pyrazolyl, pyridyl, pyrimidinyl, indazolyl, benzotriazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzodioxanyl, and tetrahydrobenzazepinyl.

### Claim 6 (depends on 1)

The compound or salt of claim 1, wherein A is phenyl.

### Claim 7 (depends on 1)

The compound or salt of claim 1, wherein the compound is a compound of Formula (I-B):

### Claim 8 (depends on 1)

The compound or salt of claim 1, wherein the compound is a compound of Formula (I-C):

### Claim at position 8

-10. (canceled)

### Claim 11 (depends on 1)

The compound or salt of claim 1, wherein RA is independently selected at each occurrence from:
halogen, —OR1, —N(R1)2, —S(═O)2R1, —S(═O)2N(R1)2, —NR1S(═O)2R1, —NR1S(═O)2N(R1)2, —C(O)R1, —C(O)OR1, —NR1C(O)R1, —NR1C(O)N(R1)2, —C(O)N(R1)2;
C1-6 alkyl and —N(R1)—C1-10 alkyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from —OR1, —N(R1)2, and 3- to 10-membered heterocycle; and
3- to 10-membered heterocycle,
wherein each 3- to 10-membered heterocycle in RA is independently optionally substituted with one or more substituents selected from —OR1, —N(R1)2, —C(O)R1, —CH2C(O)OR1, —C(O)OR1, —C(O)N(R1)2, and R1.

### Claim at position 10

-13. (canceled)

### Claim 14 (depends on 1)

The compound or salt of claim 1, wherein RA is —NR1C(O)R1.

### Claim 15 (depends on 1)

The compound or salt of claim 1, wherein RA is —C(O)OR1.

### Claim 16 (depends on 1)

The compound or salt of claim 1, wherein RA is C1-6 alkyl substituted with 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is substituted with —C(O)OR1.

### Claim at position 14

-21. (canceled)

### Claim 22 (depends on 1)

The compound or salt of claim 1, wherein m is 1.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The compound or salt of claim 1, wherein B is selected from phenyl and pyridyl.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The compound or salt of claim 1, wherein B is 2-pyridyl.

### Claim 27

(canceled)

### Claim 28 (depends on 1)

The compound or salt of claim 1, wherein RB is independently selected at each occurrence from halogen, —OH, —CH3, and —CHF2.

### Claim 29 (depends on 1)

The compound or salt of claim 1, wherein RB is —CH3.

### Claim 30

(canceled)

### Claim 31 (depends on 1)

The compound or salt of claim 1, wherein n is 1.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The compound or salt of claim 1, wherein the compound is a compound of Formula (I-E):

### Claim at position 27

-40. (canceled)

### Claim 41 (depends on 1)

A pharmaceutical composition comprising the compound or salt of claim 1 a pharmaceutically acceptable carrier.

### Claim at position 29

-43. (canceled)

### Claim 44 (depends on 1)

A method of treating an ALK5-mediated disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of the compound or salt of claim 1.

### Claim 45

(canceled)

### Claim 46 (depends on 44)

The method of claim 44, wherein the disease or condition is fibrosis.

### Claim at position 33

-50. (canceled)

### Claim 51 (depends on 46)

The method of claim 46, where the fibrosis is idiopathic pulmonary fibrosis (IPF).

### Claim 52 (depends on 46)

The method of claim 46, wherein the fibrosis is intestinal fibrosis.

### Claim 53

(canceled)

### Claim 54 (depends on 44)

The method of claim 44, wherein the disease or condition is selected from breast cancer, colon cancer, prostate cancer, lung cancer, hepatocellular carcinoma, glioblastoma, melanoma, and pancreatic cancer.

### Claim at position 38

-63. (canceled)
